Group One Trading’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-20,900
| Closed | -$274K | – | 7622 |
|
|
2025
Q4 | $274K | Buy |
20,900
+19,900
| +1,990% | +$238K | ﹤0.01% | 4087 |
|
|
2025
Q3 | $7.28K | Buy |
1,000
+900
| +900% | +$6.09K | ﹤0.01% | 7359 |
|
|
2025
Q2 | $536 | Buy |
+100
| New | +$485 | ﹤0.01% | 7651 |
|
|
2024
Q3 | – | Sell |
-600
| Closed | -$5.46K | – | 6624 |
|
|
2024
Q2 | $5.46K | Sell |
600
-86,300
| -99% | -$842K | ﹤0.01% | 5913 |
|
|
2024
Q1 | $1.22M | Buy |
86,900
+83,600
| +2,533% | +$1.04M | ﹤0.01% | 1904 |
|
|
2023
Q4 | $25.3K | Buy |
+3,300
| New | +$18.2K | ﹤0.01% | 5570 |
|
|
2023
Q2 | – | Sell |
-100
| Closed | -$1.33K | – | 7622 |
|
|
2023
Q1 | $1.33K | Sell |
100
-2,500
| -96% | -$33.8K | ﹤0.01% | 6717 |
|
|
2022
Q4 | $38.7K | Hold |
2,600
| – | – | ﹤0.01% | 5185 |
|
|
2022
Q3 | $24K | Sell |
2,600
-13,800
| -84% | -$92.5K | ﹤0.01% | 5939 |
|
|
2022
Q2 | $49K | Sell |
16,400
-60,200
| -79% | -$270K | ﹤0.01% | 5565 |
|
|
2022
Q1 | $514K | Buy |
76,600
+17,000
| +29% | +$101K | ﹤0.01% | 3779 |
|
|
2021
Q4 | $321K | Buy |
59,600
+49,600
| +496% | +$326K | ﹤0.01% | 4597 |
|
|
2021
Q3 | $88K | Buy |
10,000
+2,400
| +32% | +$23K | ﹤0.01% | 6032 |
|
|
2021
Q2 | $96K | Sell |
7,600
-3,283
| -30% | -$42.6K | ﹤0.01% | 6001 |
|
|
2021
Q1 | $189K | Buy |
10,883
+4,333
| +66% | +$78.3K | ﹤0.01% | 5085 |
|
|
2020
Q4 | $84K | Buy |
+6,550
| New | +$117K | ﹤0.01% | 4679 |
|
Group One Trading's ATXS Position: Q4 2025 in Review
Group One Trading sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 100 shares — an estimated $1.19K sold.
Group One Trading first reported a position in ATXS in Q3 2020 and held it in 15 quarters. The position peaked at $445K in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.
- Group One Trading reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
- Group One Trading sold 100 Astria Therapeutics shares in Q4 2025, an estimated $1.19K.
- Group One Trading first reported a position in Astria Therapeutics in Q3 2020 and held it in 15 quarters.
- Group One Trading's Astria Therapeutics position peaked at $445K in Q1 2024.
- 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.
Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.